Our People

Paul A. Grayson
President and Chief Executive Officer

Mr. Paul Grayson previously served as CEO of Fate Therapeutics (NASDAQ: FATE). Before this, he was managing director of Sanderling Ventures. Prior to Sanderling, Mr. Grayson served as the founding Chairman and CEO of Senomyx Inc. (NASDAQ: SNMX).

Alan Glicklich, MD
Chief Medical Officer

Dr. Alan Glicklich previously served as vice president of clinical development of Arena Pharmaceuticals. Prior to Arena, he was the vice president of clinical affairs of Savient Pharmaceuticals and before that the vice president of clinical development of Veloxis Pharmaceuticals. Dr. Glicklich has also served in senior clinical positions at Mitsubishi-Tanabe Development America, Bristol Myers Squibb, Sanofi-Aventis and Regeneron. He holds a medical degree from the University of Wisconsin, an MBA from Emory University and BA in Biology from the University of Chicago.

Anke Kretz-Rommel, Ph.D.
Chief Technology Officer

Dr. Anke Kretz-Rommel has more than 20 years of experience in discovering and developing antibodies for the treatment of cancer, autoimmune and inflammatory diseases. She has developed multiple protein therapeutic platforms yielding clinical drug candidates including the anti-CB1 antibody nimacimab. She has led the preclinical development and transition into the clinic of multiple antibodies, and currently oversees CMC, toxicology and pharmacology activities of Bird Rock Bio’s antibody programs. Prior to Bird Rock Bio, she led multiple discovery and development efforts as head of the Cellular Immunology group at Alexion Antibody Technologies. Dr. Kretz-Rommel received her Ph.D. in toxicology from the ETH Zurich, Switzerland.

Alyssa Lochbaum
Vice President Finance

Alyssa is a Chartered Accountant (Canada) with a strong background in healthcare finance and accounting. She spent eight years with the public accounting firm PricewaterhouseCoopers LLP in San Diego and Vancouver, Canada working in both the Audit and Advisory practices and was previously the Vice President of Finance and Controller at Cosmederm Bioscience in San Diego. She holds a Bachelor of Arts from the University of British Columbia and a Masters in Professional Accountancy from the University of Saskatchewan.

Shay Tabani
Global Head of Quality

Shay has over 25 years of experience in Pharma/Biotech Quality Management Systems and academia. Since joining Bird Rock Bio in January 2017 she has coordinated all aspects of the Quality Program, with ultimate responsibility and authority for releasing or rejecting product (APIs/ bulk drug substance and drug product/ finished dosage form) and certifying conformance with applicable cGMPs. Shay is also a Life Science Instructor at UCSD Extension. She previously worked as Site Head of Development Quality for Sandoz, Novartis GNF-BDU, Teva Parenteral Medicines, and as Senior Director QA at Avid Bioservices. Shay has a Masters in Physical Chemistry from University of Karachi, Pakistan, and has several professional certificates, including Regulatory Affairs Certificate from RAPS, Certified Quality Manager Preparation from Irvine Valley College and Deviation Management and Effective CAPAs from KT and NSF-DBA. Shay is also a member of professional societies, PDA, RAPS, OCRA and ASQ.

Roger Ferrini, Ph.D.
Head of Antibody Discovery Technology

Roger Ferrini received his PhD from UCLA where he studied lymphocyte development. He then worked on apoptosis as a post-doctoral fellow at the Immune Disease Institute at Harvard Medical School. Dr. Ferrini joined Bird Rock Bio in 2009, where he worked with a team developing the Atrimer platform, an alternative antigen binding scaffold technology. In 2012 he joined the team in Shanghai, China, where he helped establish laboratory operations and lead the team that identified the RYI-018 (nimacimab) molecule using the iCAPS technology platform. Currently, as Head of Antibody Technologies, Dr. Ferrini is part of a small core team that oversees CMC operations, preclinical studies and continued development of the iCAPS platform.

Jerlyn Tolentino
Director of Clinical Operations

Jerlyn has spent eight years working at several universities and hospitals as a clinical research coordinator and research manager. She worked at PAREXEL International as a Senior Clinical Trial Specialist reviewing regulatory documents and then at Intercept Pharmaceuticals, Inc. as a Senior Clinical Trial Associate. She holds a Bachelor of Science from the University of California, Los Angeles and a Master of Arts in Psychology from San Diego State University.

Tara Vargas
Project Manager

Tara leads project management at Bird Rock Bio and is responsible for clinical research, manufacturing and toxicology project activities. In addition, Tara also plays an important role in clinical operations and vendor management. A graduate of California State University Fullerton, Tara joined Bird Rock Bio in 2014 with 5 years of previous project management experience in Australia and the US.

Kenneth Huang
Finance Manager

Kenneth joined Bird Rock Bio in 2014 and has over 10 years of experience working in finance and accounting for both public and private companies. Since joining Bird Rock Bio in 2014, he has managed the all aspects of the accounting, finance and HR functions. He holds a B.S. in Management Science from the University of California, San Diego.

Colleen Daley
Project Associate

Colleen is a recent graduate of University of California San Diego and joined Bird Rock Bio in early 2017. She supports project management activities on both the clinical research and manufacturing side of the company. In addition, Colleen oversees day-to-day office operations to ensure all aspects of the company are running smoothly.